X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUN PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUN PHARMA NOVARTIS/
SUN PHARMA
 
P/E (TTM) x 435.8 32.3 1,350.7% View Chart
P/BV x 30.8 2.7 1,140.1% View Chart
Dividend Yield % 1.5 0.5 317.5%  

Financials

 NOVARTIS   SUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
SUN PHARMA
Mar-18
NOVARTIS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs758701 108.2%   
Low Rs579433 133.7%   
Sales per share (Unadj.) Rs228.4110.4 206.9%  
Earnings per share (Unadj.) Rs31.711.0 289.1%  
Cash flow per share (Unadj.) Rs32.817.2 190.2%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.4 424.0%  
Book value per share (Unadj.) Rs297.1158.8 187.1%  
Shares outstanding (eoy) m24.692,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.95.1 57.0%   
Avg P/E ratio x21.151.6 40.8%  
P/CF ratio (eoy) x20.432.9 62.0%  
Price / Book Value ratio x2.23.6 63.0%  
Dividend payout %31.518.2 172.9%   
Avg Mkt Cap Rs m16,5051,360,021 1.2%   
No. of employees `0000.717.8 3.8%   
Total wages/salary Rs m1,44553,671 2.7%   
Avg. sales/employee Rs Th8,441.314,890.9 56.7%   
Avg. wages/employee Rs Th2,163.63,017.1 71.7%   
Avg. net profit/employee Rs Th1,173.11,480.6 79.2%   
INCOME DATA
Net Sales Rs m5,639264,895 2.1%  
Other income Rs m1,7188,388 20.5%   
Total revenues Rs m7,357273,282 2.7%   
Gross profit Rs m-6356,081 -0.1%  
Depreciation Rs m2514,998 0.2%   
Interest Rs m555,176 1.1%   
Profit before tax Rs m1,57544,295 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m7928,452 9.4%   
Profit after tax Rs m78426,338 3.0%  
Gross profit margin %-1.121.2 -5.2%  
Effective tax rate %50.319.1 263.4%   
Net profit margin %13.99.9 139.8%  
BALANCE SHEET DATA
Current assets Rs m9,522316,359 3.0%   
Current liabilities Rs m3,296198,643 1.7%   
Net working cap to sales %110.444.4 248.4%  
Current ratio x2.91.6 181.4%  
Inventory Days Days3795 38.6%  
Debtors Days Days28108 26.4%  
Net fixed assets Rs m46213,178 0.0%   
Share capital Rs m1232,399 5.1%   
"Free" reserves Rs m7,213378,606 1.9%   
Net worth Rs m7,336381,006 1.9%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m11,105643,028 1.7%  
Interest coverage x29.59.6 308.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.4 123.3%   
Return on assets %7.64.9 154.1%  
Return on equity %10.76.9 154.5%  
Return on capital %22.210.0 221.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6140,816 0.1%   
Fx outflow Rs m3,63030,143 12.0%   
Net fx Rs m-3,57010,673 -33.4%   
CASH FLOW
From Operations Rs m1,61039,072 4.1%  
From Investments Rs m687-33,708 -2.0%  
From Financial Activity Rs m-2,677-15,393 17.4%  
Net Cashflow Rs m-380-7,359 5.2%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.1 39.0%  
FIIs % 1.6 23.0 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.3 259.0%  
Shareholders   41,647 133,026 31.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; Metal & Automobile Stocks Slip(12:30 pm)

Share markets in India are presently trading on a negative note. Barring finance sector, all sectoral indices are trading in red with stocks in the metal sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 18, 2019 03:05 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - DR. REDDYS LAB COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS